STOCK TITAN
  1. Home
  2. News
  3. LIXT

Lixte Biotechnology Holdings Inc - LIXT STOCK NEWS

Welcome to our dedicated news page for Lixte Biotechnology Holdings (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lixte Biotechnology Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lixte Biotechnology Holdings's position in the market.

News
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. announces a groundbreaking discovery that its lead clinical compound, LB-100, can force cancer cells to become less cancerous, opening up a new treatment strategy. The pre-clinical data published in Cancer Discovery shows that LB-100, when combined with a WEE1 kinase inhibitor, is highly effective in killing colon cancer cells. The unique feature of LB-100 is its ability to hyper-activate cancer signals, leading to cancer cells becoming less malignant and unable to form tumors. This 'tumor suppressive drug resistance' concept could revolutionize cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.1%
Tags
none
-
News
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. provides an update on three ongoing clinical trials for treating ovarian, lung, and sarcoma cancers. The company is developing a new cancer therapy using LB-100 to enhance chemotherapy and immunotherapy. Significant developments include dosing the first patient in a Phase 1b/2 trial with GSK's dostarlimab-gxly for ovarian clear cell carcinoma, an exclusive patent license agreement with NIH, and new pre-clinical data presented by Dr. René Bernards on LB-100's unique mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
News
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. presents new pre-clinical data on their lead compound LB-100 at a cancer research conference in Dublin. The data shows how LB-100 drives cancer cells to evolve into less aggressive behavior, positioning it as a promising cancer therapy. LIXTE also enters into a Patent License Agreement with NIH and initiates a clinical trial to assess LB-100's effectiveness in combination with immunotherapy for ovarian clear cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.81%
Tags
conferences clinical trial
News
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. signs exclusive patent license agreement with NIH to develop innovative cancer immunotherapies. The collaboration aims to combine LIXTE's LB-100 with various cancer treatments to enhance anti-cancer activity. Clinical trials are underway to evaluate LB-100's potential in combination with checkpoint inhibitors and chemotherapy for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
News
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a Phase 1b/2 clinical trial to evaluate the potential of adding LB-100 to GSK's dostarlimab-gxly in treating ovarian clear cell carcinoma. The trial is conducted at The University of Texas MD Anderson Cancer Center, based on the observation that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody in patients with OCCC lacking the genetic reduction in PP2A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
none
-
News
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) provides an update on its progress, including advancements in the development of LB-100, a new cancer therapy, through collaborations with GSK, The University of Texas - MD Anderson Cancer Center, and other institutions. The company also announces the appointment of Bas van der Baan as President and CEO and Chairman of the Board of Directors, following the passing of the founder. Additionally, LIXTE closed a registered direct offering and private placement, raising approximately $3,500,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
News
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. announces the passing of its founder and Executive Chairman
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
News
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Rhea-AI Summary
Bas van der Baan named President and CEO of LIXTE Biotechnology Holdings, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
Rhea-AI Summary
LIXTE announces Phase 1b clinical trial for LB-100 and dostarlimab combination in ovarian clear cell carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
none
News
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Rhea-AI Summary
LIXTE Biotechnology Holdings, Inc. has closed its registered direct offering and concurrent private placement, raising approximately $3.5 million. The offering consisted of 583,334 shares of common stock at a purchase price of $6.00 per share. The common warrants issued in the private placement have an exercise price of $6.00 per share and expire in 5 years. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
offering
Stock LIXT logo
Lixte Biotechnology Holdings Inc

Nasdaq:LIXT

LIXT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

LIXT Stock Data

7.83M
1.98M
20.48%
5.08%
0.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Pasadena

About LIXT

lixte biotechnology holdings, inc. (lixte) is a clinical-stage public (lixt) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. the current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and dna damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. the phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. the lead compound lb-100 is in phase i trial and has the potential to be first-in-class. the deacetylase in